Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours - an analysis based on the CLARINET study

Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are rare cancers most often found in the gastrointestinal system or the pancreas. However, patient-reported health state utilities based on clinical trials have not been previously reported in this disease area. The CLARINET study collected EO...

Full description

Saved in:
Bibliographic Details
Published in:Health and quality of life outcomes 2017-06, Vol.15 (1), p.131-131, Article 131
Main Authors: Meng, Yang, McCarthy, Grant, Berthon, Anthony, Dinet, Jerome
Format: Article
Language:English
Subjects:
Adult
Algorithms
Analysis
Cancer therapies
Clarinet music
Clinical trials
Colon
Consortia
Cost analysis
Disease Progression
EORTC QLQ-C30
EQ-5D
Female
Gastrointestinal system
Health
Health aspects
Health Status
Hormones
Humans
Intestinal Neoplasms - psychology
Least-Squares Analysis
Lung cancer
Male
Mapping
Mathematical models
Medical personnel
Medical research
Melanoma
Metastases
Metastasis
Middle Aged
Midgut
Models, Theoretical
Neuroendocrine Tumors - psychology
Neuroendocrine tumours
Pancreas
Pancreatic Neoplasms - psychology
Patient Outcome Assessment
Patients
Physicians
Preferences
Quality of Life
Random-effects model
Statistical analysis
Statistical significance
Stomach Neoplasms - psychology
Studies
Surveys and Questionnaires
Tumors
Utilities
Utility
Validity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are rare cancers most often found in the gastrointestinal system or the pancreas. However, patient-reported health state utilities based on clinical trials have not been previously reported in this disease area. The CLARINET study collected EORTC QLQ-C30 data from patients in both stable and progressive disease states, although data for the latter were only available during the early stage of progression due to trial design. Using published algorithms, data were mapped to EQ-5D utility values. Random-effects generalised least squares models were used to investigate the impacts of progression status, tumour site and other patient characteristics on mapped utility values. In total, 1053 observations from 204 patients were mapped to EQ-5D utilities using the McKenzie mapping algorithm. The final random-effects model included age, gender, baseline utility and progression status as covariates; it was not feasible to investigate time-to-death utility due to a limit number of deaths in the CLARINET study. Tumour location (midgut vs pancreas) does not seem to affect utility. However, the difference in utilities based on progression status is statistically significant (p 
ISSN:1477-7525
1477-7525
DOI:10.1186/s12955-017-0711-z